Onco-Innovations Limited (ONNVF)
| Market Cap | 28.43M -59.8% |
| Revenue (ttm) | 81.09K +69.1% |
| Net Income | -7.92M |
| EPS | -0.14 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 273 |
| Open | 0.4500 |
| Previous Close | 0.4388 |
| Day's Range | 0.4492 - 0.4500 |
| 52-Week Range | 0.3870 - 1.3200 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Onco-Innovations
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company’s lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3′-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities... [Read more]
Financial Performance
In fiscal year 2026, Onco-Innovations's revenue was 110,378, an increase of 69.06% compared to the previous year's 65,291. Losses were -10.78 million, 42.5% more than in 2025.
Financial numbers in CAD Financial StatementsNews
Onco-Innovations Reports Progress Toward a Consistent and Scalable Polymer Manufacturing Process Supporting ONC010
Vancouver, Canada – July 30, 2026 - TheNewswire – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H , WKN: A3EKSZ) (" Onco " or the " Company ”) is pleased to announce, furthe...
Onco-Innovations Announces Initial Closing of Notional CAD$5 Million Performance-Based Funding Arrangement
Vancouver, Canada – July 29, 2026 – TheNewswire - Onco-Innovations Limited (CBOE: ONCO) (“ Onco ” or the “ Company ”) is pleased to announce that it has closed its previously announced non-brokered p...
Onco-Innovations Announces Repricing of Previously Announced Performance-Based Funding Arrangement
Vancouver, Canada – July 27, 2026 – TheNewswire - Onco-Innovations Limited (CBOE: ONCO) (“ Onco ” or the “ Company ”) announces that, further to its previously announced non-brokered private placemen...
Onco-Innovations Initiates ADME Studies Supporting Development of ONC010
Vancouver, Canada – July 16, 2026 – TheNewswire - Onco-Innovations Limited ( CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H , WKN: A3EKSZ) (" Onco " or the " Company ”) announces, further to its new...
Onco-Innovations Announces Entry into Loan Agreements
Vancouver, Canada – July 15, 2026 - TheNewswire – Onco-Innovations Limited (CBOE: ONCO) (“ Onco ” or the “ Company ”) announces that it has entered into three loan agreements with certain lenders pro...
Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API
VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its ...
Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Com...
Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news...
Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
VANCOUVER, BC / ACCESS Newswire / June 26, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the initiation of hepatocyte and...
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Development of PNKP Inhibitors in Oncology Drug Development
AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featur...
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of...
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / Onco-Innovations Limited (NEO:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a...
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "...
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
VANCOUVER, BC / ACCESS Newswire / June 16, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news...
Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the initiation of pro...
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
VANCOUVER, BC / ACCESS Newswire / June 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered i...
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Also Announces Marketing Program VANCOUVER, BC / ACCESS Newswire / June 2, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") announces,...
Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news ...
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
VANCOUVER, BC / ACCESS Newswire / May 15, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advanced ...
Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Aim is to Predict Oncology Outcomes using Multimodal Artificial Intelligence VANCOUVER, BC / ACCESS Newswire / May 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A...
Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
VANCOUVER, BC / ACCESS Newswire / May 8, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that Nucro-Technics Inc. ("Nucro-Tec...
Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation
VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ...
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Also Announces Extension of IR Program VANCOUVER, BC / ACCESS Newswire / May 1, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pl...
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announced, further to its news release date...
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advance...